FDA warns of heart risk with HIV drug combination

Oct 21, 2010

(AP) -- The Food and Drug Administration is warning HIV patients not to combine two widely used antiviral drugs because they can cause dangerous heart rhythms.

The agency says the combination of Roche's Invirase and Abbott Laboratories' Norvir can trigger irregular heartbeats, leading to fainting, lightheadedness and even death. The FDA is requiring the companies to add information about the risk to their drugs' warning labels and to distribute pamphlets to patients.

Patients with HIV generally cycle through combinations of medicines to control the virus, which attacks the immune system.

The FDA approved Invirase in 1995 to lower HIV levels in the blood. It is often combined with Norvir to improve its effectiveness.

More than 1.1 million people in the U.S. have , according to the Centers for Disease Control and Prevention.

Explore further: Expression of privilege in vaccine refusal

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA approves antiretroviral drug

Aug 07, 2007

The U.S. Food and Drug Administration has approved the antiretroviral drug maraviroc for use in adult human immunodeficiency virus patients.

FDA orders new Nonoxynol-9 warning

Dec 18, 2007

The U.S. Food and Drug Administration issued a final rule Tuesday requiring manufacturers of nonoxynol-9, or N9, to add a warning to the product's label.

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

Recommended for you

Expression of privilege in vaccine refusal

11 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments : 0